Safety of Regadenoson in Patients with End-Stage Renal Disease
- 1 January 2010
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 105 (1) , 133-135
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Automated assessment of serial SPECT myocardial perfusion imagesJournal of Nuclear Cardiology, 2009
- Role of Myocardial Perfusion Imaging in Patients With End-Stage Renal Disease Undergoing Coronary AngiographyThe American Journal of Cardiology, 2008
- Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion ImagingJACC: Cardiovascular Imaging, 2008
- Myocardial perfusion and function: Single photon emission computed tomographyJournal of Nuclear Cardiology, 2007
- Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trialJournal of Nuclear Cardiology, 2007
- Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal FunctionThe Journal of Clinical Pharmacology, 2007
- Corridor4DM: The Michigan method for quantitative nuclear cardiologyJournal of Nuclear Cardiology, 2007
- Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humansJournal of Nuclear Cardiology, 2007
- Pharmacologic stress myocardial perfusion imaging: A practical approachJournal of Nuclear Cardiology, 2007
- A Population Pharmacokinetic/Pharmacodynamic Analysis of Regadenoson, an Adenosine A2A-Receptor Agonist, in Healthy Male VolunteersClinical Pharmacokinetics, 2006